Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Trovagene Inc (NQ: TROV )

1.190 USD UNCHANGED
Last Price Updated: 6:26 PM EDT, May 7, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Trovagene Inc

< Previous 1 2 3 4 5 6 Next >
Trovagene Announces First Quarter 2020 Results and Highlights
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer,... 
From PR Newswire
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
- New corporate name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients 
From PR Newswire
16 Healthcare Stocks Moving In Wednesday's Pre-Market Session
Gainers • Chimerix, Inc. (NASDAQ:CMRX) shares increased by 38.41% to $2.09 during Wednesday's pre-market session. • ... 
Tags MRKR Trading Ideas Healthcare Stocks Pre/Market Movers
From Benzinga
Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response
- Ongoing Phase 1b/2 trial has enrolled 12 patients with 88% response in 7 of 8 evaluable patients; to-date 3 patients with a partial response (PR); 4 patients with stable disease (SD) 
From PR Newswire
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal,... 
From PR Newswire
Trovagene to Present at the 19th Annual Needham Healthcare Conference
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers... 
From PR Newswire
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, announced today... 
From PR Newswire
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit ... 
Tags Biotech VCEL SSKN
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday morning, 1178 companies hit new 52-week lows. Facts of Interest: The largest company by market cap to set a new ... 
Tags EXPI NCV CVNA
From Benzinga
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags HOOK XBI NVCN
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 1526 stocks hit new 52-week lows. Facts of Interest: Facebook(NASDAQ: FB)was the largest firm on a ... 
Tags VIOT Movers YPF
From Benzinga
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags ACST MYGN Earnings
From Benzinga
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit ... 
Tags RGLS REPL PGNX
From Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 2568 stocks hit new 52-week lows. Areas of Significance: Amazon.com(NASDAQ: AMZN)is the largest company ... 
Tags CSV CVX MBOT
From Benzinga
Trovagene Announces Three New Nominees for Election to Board of Directors
Nominees bring extensive expertise in the fields of oncology drug development and commercialization, biopharmaceutical company financing and strategic operations 
From PR Newswire
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers... 
From PR Newswire
77 Biggest Movers From Yesterday
Gainers Revolution Medicines, Inc. (NASDAQ: RVMD) shares surged 70% to close at $28.90 on Thursday. Revolution Medicines priced 14 ... 
Tags DCPH CTL SURF
From Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Gainers CounterPath Corporation (NASDAQ: CPAH) shares climbed 46.5% to $3.1487 after the company announced it has secured a ... 
Tags VXRT Information Technology Top Gainers
From Benzinga
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags BLPH BEAM FDA
From Benzinga
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
- Onvansertib demonstrates efficacy in Zytiga®-resistant metastatic castration-resistant prostate cancer (mCRPC) across known androgen receptor resistance mechanisms 
From PR Newswire
4 Penny Stocks To Watch Under $3 This Week
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight
Biotech stocks recovered last week along with the broader markets, which bounced back from a China coronavirus-induced sell-off. Big ... 
Tags ABBV UROV IRWD
From Benzinga
Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and leukemia, today announced... 
From PR Newswire
Agencies Expect Possible Treatments and Hope for a Coronavirus Vaccine as Soon as Three Months
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Agencies Expect Possible Treatments and Hope for a Coronavirus Vaccine as Soon as Three Months
FN Media Group Presents USA News Group Market Commentary 
From PR Newswire
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers... 
From PR Newswire
5 Penny Stocks Trading Higher This Week; 1 Up 690% This Month
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients
- All patients showed tumor regression by radiographic scan at 8 weeks and confirmation by further tumor shrinkage at 16 weeks; clinical benefit achieved in 100% (n=5) of patients 
From PR Newswire
4 Penny Stocks To Watch Expecting Key Data Soon
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
98 Biotechnology Stocks Moving In Wednesday's Session
Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock increased by 131.7% to $3.36 during Wednesday's regular session. • ... 
Tags CDTX CLVS ETON
From Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account